Santhera Pharmaceuticals Holding AG (SANN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Santhera Pharmaceuticals Holding AG (SANN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10158
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Santhera Pharmaceuticals Holding AG (Santhera) develops and commercializes novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. It specifically focuses in the area of neuromuscular and neuro-ophthalmological conditions. The company’s lead product candidate, Raxone (idebenone), is developed for the treatment of Leber’s hereditary optic neuropathy (LHON). Raxone is also investigated for other diseases such as Duchenne muscular dystrophy and primary progressive multiple sclerosis. Santhera’s pipeline also includes other compounds, namely, omigapil for congenital muscular dystrophies. It operates along with its subsidiaries located in Switzerland, Germany, Canada, Finland and the US. Santhera is headquartered in Pratteln, Switzerland.

Santhera Pharmaceuticals Holding AG (SANN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Santhera Pharma Enters into Distribution Agreement with Pharmathen Pharma 10
Licensing Agreements 11
Santhera Pharma Enters into Licensing Agreement with Polyphor 11
Equity Offering 12
Santhera Pharma Raises USD53.3 Million in Private Placement of Shares 12
Santhera Pharma Raises USD28 Million through Private Placement of Shares 13
Santhera Pharma Raises USD15 Million in Public Offering of Shares 14
Santhera Pharma Completes Private Placement Of Shares For US$1 Million 15
Santhera Pharma Announces Private Placement Of Units For US$11 Million 16
Debt Offering 17
Santhera Pharma Raises USD60.2 Million in Public Offering of 5% Bonds Due 2022 17
Santhera Pharmaceuticals Holding AG – Key Competitors 18
Santhera Pharmaceuticals Holding AG – Key Employees 19
Santhera Pharmaceuticals Holding AG – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Sep 04, 2018: Santhera Announces Financial Results for the First Half-Year 2018 and Updates on Operational Progress and Growth Strategy 21
Mar 20, 2018: Santhera Reports Solid Top-line Growth in 2017 and Reiterates its Strategy to Obtain Approval for Idebenone in Duchenne Muscular Dystrophy 23
Jan 29, 2018: Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update 25
Sep 05, 2017: Santhera Announces Financial Results for the First Half-Year 2017 and Reports Commercial and Development Progress 27
Mar 07, 2017: Santhera Delivered Solid Performance in 2016 and Advances All Programs 28
Jan 26, 2017: Santhera Reports Preliminary Key Financial Figures For 2016 And Provides Corporate Update 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Santhera Pharmaceuticals Holding AG, Deals By Therapy Area, 2012 to YTD 2018 8
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Santhera Pharma Enters into Distribution Agreement with Pharmathen Pharma 10
Santhera Pharma Enters into Licensing Agreement with Polyphor 11
Santhera Pharma Raises USD53.3 Million in Private Placement of Shares 12
Santhera Pharma Raises USD28 Million through Private Placement of Shares 13
Santhera Pharma Raises USD15 Million in Public Offering of Shares 14
Santhera Pharma Completes Private Placement Of Shares For US$1 Million 15
Santhera Pharma Announces Private Placement Of Units For US$11 Million 16
Santhera Pharma Raises USD60.2 Million in Public Offering of 5% Bonds Due 2022 17
Santhera Pharmaceuticals Holding AG, Key Competitors 18
Santhera Pharmaceuticals Holding AG, Key Employees 19
Santhera Pharmaceuticals Holding AG, Subsidiaries 20

List of Figures
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Santhera Pharmaceuticals Holding AG (SANN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lantern Pharma Inc-製薬・医療分野:企業M&A・提携分析
    Summary Lantern Pharma Inc (Lantern Pharma) is a drug development company that discovers and develops therapies for various cancer types. The company’s pipeline products include Irofulven-1, an anti-tumor agent is developed to fight against multi-drug resistant cancers. Its Irofulven-1 is used for t …
  • Wake Forest Innovations-製薬・医療分野:企業M&A・提携分析
    Summary Wake Forest Innovations (Wake Forest), a subsidiary of Wake Forest Baptist Medical Center, is an enterprise that advances the development and commercialization of discoveries; services; and products such as medicines and vaccines, from the Medical Center and Wake Forest University. The compa …
  • Oxford Gene Technology Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Oxford Gene Technology Ltd (OGT) is a provider of genetics research solutions. The company’s products comprise fish probes, custom cancer panels, custom AML panel, custom breast cancer panel, custom FH panel, core MPN panel, ovarian cancer panel, myeloid panel and others. It provides medical …
  • Singapore Telecommunications Ltd:企業の戦略・SWOT・財務情報
    Singapore Telecommunications Ltd - Strategy, SWOT and Corporate Finance Report Summary Singapore Telecommunications Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • TenneT Holding BV:企業の戦略的SWOT分析
    TenneT Holding BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Bird Rock Bio Inc-製薬・医療分野:企業M&A・提携分析
    Summary Bird Rock Bio Inc (Bird Rock Bio), formerly RuiYi Inc is a clinical stage biopharmaceutical company that develops immuno-inflammatory regulators. The company’s products under development include RYI-018 is a peripheral antagonist antibody to cannabinoid receptor 1 intended for the treatment …
  • Mitsui O.S.K. Lines Ltd (9104):石油・ガス:M&Aディール及び事業提携情報
    Summary Mitsui O.S.K. Lines Ltd (MOL) is a global marine logistic company. It owns and operates dry bulkers, tankers, LNG carriers, containerships, ferries & coastal RoRo ships, cruise ships. The company’s dry bulkers transport dry bulk cargo such as iron ore, coal, grains, wood, wood chips, cement, …
  • AstraZeneca AB-製薬・医療分野:企業M&A・提携分析
    Summary AstraZeneca AB (AstraZeneca), a subsidiary of AstraZeneca Plc is a healthcare products provider that research and development of medicinal products. The company offers research and produces drug products in heart and cardiovascular, infection, cancer, metabolic diseases, respiratory, stomach …
  • Stamps com Inc (STMP):企業の財務・戦略的SWOT分析
    Stamps com Inc (STMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • China Banking Corporation:企業の戦略・SWOT・財務情報
    China Banking Corporation - Strategy, SWOT and Corporate Finance Report Summary China Banking Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Clarion Co Ltd:企業の戦略的SWOT分析
    Clarion Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Wenzel Downhole Tools Ltd:企業の戦略的SWOT分析
    Wenzel Downhole Tools Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • MidAmerican Energy Co:電力:M&Aディール及び事業提携情報
    Summary MidAmerican Energy Company (MidAmerican Energy), a subsidiary of Berkshire Hathaway Energy, is a regulated electric and natural gas utility company that carries out the generation, transmission and distribution and selling of electricity. The company also undertakes distribution, selling and …
  • Aptuit LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Aptuit LLC (Aptuit) is a developer and manufacturer of pharmaceutical drug. The company offers drug design and discovery, IND enabling programs, integrated chemistry, manufacture and control and indigo. It drug discovery capabilities includes medicinal chemistry, computational chemistry, pha …
  • NH Foods Ltd.:企業の戦略・SWOT・財務情報
    NH Foods Ltd. - Strategy, SWOT and Corporate Finance Report Summary NH Foods Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Electromed Inc (ELMD):企業の財務・戦略的SWOT分析
    Summary Electromed Inc (Electromed) is a medical device company that designs, manufactures and markets respiratory care products using airway clearance technologies. The company offers smartvest airway clearance system used through in-home and in-patient therapies for respiratory treatments. It offe …
  • Enmax Corporation:電力:M&Aディール及び事業提携情報
    Summary ENMAX Corporation (ENMAX), a subsidiary of City of Calgary, is a vertically integrated energy utility. It generates, transmits and distributes electricity; supplies natural gas; and provides value-added services. Through its subsidiaries, the company undertakes deregulated electricity genera …
  • Schott AG:企業の戦略的SWOT分析
    Schott AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Mamee-Double Decker (M) Berhad:企業の戦略的SWOT分析
    Mamee-Double Decker (M) Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • NantKwest Inc (NK):企業の財務・戦略的SWOT分析
    Summary NantKwest Inc (NantKwest), a subsidiary of NantWorks LLC, develops natural killer (NK) cell therapies to treat cancer, infectious and inflammatory diseases by harnessing the immune system. The company is developing drugs against Merkel cell carcinoma 2L, non-small cell lung cancer 3L, multip …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆